Loading clinical trials...

A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Clinical Trials | Clareo Health

COMPLETEDPHASE3

A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Randomized, Double-blind Study of the Effect of Avastin Plus Cisplatin and Gemcitabine or Placebo Plus Cisplatin and Gemcitabine on Progression-free Survival in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC

NCT00806923•Hoffmann-La Roche

View on ClinicalTrials.gov

Summary

This 3 arm study will evaluate the efficacy and safety of adding Avastin versus placebo to a standard chemotherapeutic regimen in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) who have not received prior chemotherapy. The anticipated time of study treatment is until disease progression, and the target sample size is 500+ individuals.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•adult patients, \>=18 years of age;
•documented inoperable, locally advanced, metastatic or recurrent non-squamous NSCLC;
•adequate liver and kidney function;
•women of childbearing potential must have a negative serum pregnancy test within 7 days of starting study treatment.

Exclusion Criteria

•prior chemotherapy or treatment with another systemic cancer therapy;
•surgery (including open biopsy), significant traumatic injury, or radiotherapy within the last 4 weeks prior to first dose of study treatment;
•brain metastasis or spinal cord compression;
•fertile men, and women of childbearing potential, not using adequate contraception;
•treatment with any other investigational agent, or participation in another clinical trial, within 30 days prior to entering the study.

Locations (154)

Bahía Blanca, Argentina

Buenos Aires, Argentina

Mendoza, Argentina

San Miguel de Tucumán, Argentina

Santa Fe, Argentina

Adelaide, Australia

Brisbane, Australia

Key Dates

Start Date

February 1, 2005

Primary Completion Date

February 1, 2011

Completion Date

February 1, 2011

Last Updated

November 2, 2016

Enrollment

1,044

ACTUAL participants

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

Cisplatin

DRUG

Gemcitabine

DRUG

Placebo

DRUG

bevacizumab [Avastin]

DRUG

bevacizumab [Avastin]

DRUG

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

NCT06627647

Non-squamous Non-small Cell Lung Cancer

View study

RECRUITINGPHASE2/PHASE3

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT06417008

Non-Squamous Non-Small Cell Lung Cancer

View study

ACTIVE_NOT_RECRUITINGPHASE3

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 2, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria

Exclusion Criteria

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Paclitaxel-bevacizumab in Advanced Lung Cancer

A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).